Lancashire and South Cumbria
Formulary
Formulary
8 Malignant disease and immunosuppression
The majority of systemic anti-cancer therapies are not listed in this formulary as they are included in either the Lancashire and South Cumbria Cancer Alliance SACT protocols or the Cancer Drugs Fund list, produced by NHSE. |
08-02 Drugs affecting the immune response
| Ozanimod Zeposia® |
|
Formulary
|
Capsules 230microgram, 460microgram, 920 microgram
|
 NICE TA706: Ozanimod for treating relapsing–remitting multiple sclerosis NICE TA828: Ozanimod for treating moderately to severely active ulcerative colitis |
|
NICE TA828: Ozanimod for treating moderately to severely active ulcerative colitis 
NICE TA706: Ozanimod for treating relapsing–remitting multiple sclerosis
Links
- LSC Breast Chemotherapy Protocols
- NHSE: National Cancer Drugs Fund list
- NICE NG122 : Lung cancer: diagnosis and management
- NICE NG224: Melanoma: assessment and management
- NICE NG47: Haematological cancers: improving outcomes
- NICE NG52: Non-Hodgkin’s lymphoma: diagnosis and management
- NICE TA706: Ozanimod for treating relapsing–remitting multiple sclerosis
- NICE TA706: Ozanimod for treating relapsing–remitting multiple sclerosis
- NICE TA794 : Diroximel fumarate for treating relapsing–remitting multiple sclerosis
- NICE TA794: Diroximel fumarate for treating relapsing–remitting multiple sclerosis
- NICE TA809: Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease
- NICE TA809: Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease
- NICE TA828: Ozanimod for treating moderately to severely active ulcerative colitis
- NICE TA828:Ozanimod for treating moderately to severely active ulcerative colitis